Ruth Soto-Malave

Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

Stefan Zeuzem, Graham R. Foster, Stanley Wang et al. · New England Journal of Medicine · 2018 · 437 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study

Jürgen K. Rockstroh, Karine Lacombe, Rolando M. Viani et al. · Clinical Infectious Diseases · 2018 · 147 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Lopinavir/Ritonavir Combined with Raltegravir or Tenofovir/Emtricitabine in Antiretroviral-Naive Subjects: 96-Week Results of the PROGRESS Study

Jacques Reynes, Roger Trinh, Federico Pulido et al. · AIDS Research and Human Retroviruses · 2012 · 131 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Examination of Noninferiority, Safety, and Tolerability of Lopinavir/ritonavir and Raltegravir Compared with Lopinavir/ritonavir and Tenofovir/ Emtricitabine in Antiretroviral-Naïve Subjects: The PROGRESS Study, 48-Week Results

Jacques Reynes, Adebayo Lawal, Federico Pulido et al. · HIV Clinical Trials · 2011 · 77 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and safety of Glecaprevir/Pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 Study

JK Rockstroh, Karine Lacombe, Rolando M. Viani et al. · Journal of Hepatology · 2017 · 24 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +12